Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

  • This share is currently suspended. It was suspended at a price of 7.23
  • There is currently no data for TRX

Executive Appointment

8 Feb 2005 07:00

Torex Retail PLC08 February 2005 8 February 2005 Torex Retail Appoints New CEO Torex Retail plc, the UK market leader in retail systems, is pleased to announcea significant strengthening of the executive management team. Chris Moore has been appointed as Chief Executive Officer with fullresponsibility for all executive matters. Mark Pearman will remain a key memberof the Executive Board assuming full responsibility for business development.The Company's ambitious growth plans will be spearheaded by Mark on a globalbasis through a combination of organic and acquisitive means. Rob Loosemore, Executive Chairman of Torex Retail, said: "We are delighted with these changes as we can now look forward to the immensebenefits of Chris' operational skills and Mark's ability to effect the longerterm growth of the company. We are a proven team and with our collective vigour, especially in the area oftechnology and innovation, we remain dedicated to delivering to our shareholdersand customers alike." Chris Moore background: Chris Moore, currently non-executive Chairman of the retail IT services group XNCheckout, has extensive experience with over 20 years within the IT sector. Heled the team at Torex PLC from March 1996 to April 2004, where he built up thebusiness into a European market leader in healthcare information systems and anestablished force within Retail IT. During his time at Torex, the Group grewdramatically both organically and by acquisition, with the market capitalisationgrowing from £10m to £350m. He was previously appointed non-executive DeputyChairman of Torex Retail plc on 2 November 2004. -Ends- For further information, please contact: Robert Loosemore, Executive Chairman Chris Moore, Chief ExecutiveRichard Thompson, Finance DirectorTorex Retail plcTelephone: +44 (0) 870 050 9900 Seb Hoyle / Freida MooreCitigate Dewe RogersonTelephone: +44 (0) 20 7638 9571 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
13th Nov 20249:32 amRNSForm 8.3 - Tissue Regenix Group Plc
12th Nov 20244:05 pmRNSForm 8 (OPD) (Tissue Regenix Group Plc)
12th Nov 20248:46 amRNSForm 8.5 (EPT/NON-RI)
11th Nov 20249:17 amRNSForm 8.5 (EPT/NON-RI)
7th Nov 20249:59 amRNSForm 8.5 (EPT/NON-RI) - Tissue Regenix Group PLC
6th Nov 20241:37 pmRNSForm 8.3 - Tissue Regenix Group PLC
6th Nov 20248:52 amRNSForm 8.5 (EPT/NON-RI)
5th Nov 20242:24 pmRNSForm 8.3 - Tissue Regenix Group PLC
5th Nov 202411:32 amRNSForm 8.5 (EPT/NON-RI)
4th Nov 20244:36 pmRNSResponse to media speculation
10th Sep 20247:00 amRNSInterim results for the six months ended 30 June
18th Jul 20243:52 pmRNSGrant of share options
16th Jul 20247:00 amRNSHalf-Year Trading Update
3rd Jul 20241:16 pmRNSHolding(s) in Company
24th Jun 20244:12 pmRNSHolding(s) in Company
18th Jun 20245:15 pmRNSExercise of Options, Director Dealing and TVR
14th Jun 20247:00 amRNSBuilding purchase
25th Apr 20242:27 pmRNSResult of AGM
10th Apr 20247:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth
5th Apr 20243:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSFinal results for the year ended 31 December 2023
1st Mar 20247:00 amRNSNotice of Results
6th Feb 20247:00 amRNSFirst EU shipment & new distributor agreements
29th Jan 20243:02 pmRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading update for 2023
23rd Jan 20245:24 pmRNS2023 LTIP Grant
22nd Nov 20234:36 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSHPRA approval & distribution agreement in Spain
18th Sep 202310:40 amEQSHardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
15th Sep 20234:30 pmRNSDirector/PDMR Shareholding
5th Sep 20237:01 amRNSNew sports medicine product launch
5th Sep 20237:00 amRNSInterim results
31st Aug 20231:45 pmRNSExercise of Options and Total Voting Rights
21st Aug 20237:00 amRNSNotice of interim results
17th Jul 20237:00 amRNSHalf-Year Trading Update
10th Jul 20237:00 amRNSDistribution agreement for OrthoPure® XT in the UK
25th May 20237:00 amRNSDistribution agreement with Australian Allografts
9th May 202312:00 pmRNSHolding(s) in Company
27th Apr 202312:35 pmRNSResult of AGM, Share Reorganisation &TVR
18th Apr 20237:00 amRNSProposed Share Reorganisation Timetable
5th Apr 20232:55 pmEQSHardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
5th Apr 20237:00 amRNSCEO and CFO Share Purchases
30th Mar 20237:00 amRNSHolding(s) in Company
21st Mar 20237:00 amRNSFinal results for the year ended 31 December 2022
6th Mar 20237:00 amRNSNotice of results and Investor presentation
31st Jan 20237:01 amRNSTrading update for 2022
31st Jan 20237:00 amRNSChange of Adviser
18th Jan 202310:06 amRNSHolding(s) in Company
18th Jan 20237:00 amRNSChinese distribution agreement for OrthoPure® XT
7th Dec 20227:00 amRNSProduct launch in dCELL® division

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.